Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Active, not recruiting · NCT05296512 · Registry updated 2025-12-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | female reproductive organ cancer | Active, not recruiting | Phase 2 | 2025-12-16 | NCT05296512 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Elizabeth K. Lee MD | 1 |
| Merck Sharp & Dohme LLC | 650 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 133 |
| Mayo Clinic Comprehensive Cancer Center | Rochester | United States | 6 |
| University of Chicago Medicine | Chicago | United States | 27 |